Dyadic International Inc (DYAI)

🛡️#DYAI #NASDAQ Dyadic and Scripps Research: Scalable Hantavirus Pandemic Preparedness

May 28, 2026

Dyadic Applied BioSolutions and Scripps Research have launched a collaboration to develop medical countermeasures against the hantavirus, specifically targeting the dangerous Andes virus strain. This partnership utilizes the proprietary C1 microbial platform, a fungal-based technology designed to produce vaccines and monoclonal antibodies more rapidly and affordably than traditional methods. By building on previous research into diseases like Ebola and Marburg, the initiative aims to solve critical manufacturing bottlenecks that often hinder global responses to emerging outbreaks. The effort is supported by major global health organizations, including the Gates Foundation and CEPI, to ensure high-yield production and better accessibility. Ultimately, the collaboration seeks to establish a more flexible and scalable biomanufacturing infrastructure to strengthen worldwide pandemic preparedness.

Shares to short just dropped to 35k from 500k ,it’s now listed as short sale restricted for the first time in awhile,could be run up time (I won’t be selling the 52 week quadruple bottom yet

$DYAI -Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic Production

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary Syndrome (HPS), a severe and potentially fatal respiratory disease in humans.

A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic preparedness and highlighted the need to improve the speed, scalability, flexibility, and cost-effectiveness of biologic manufacturing during rapidly evolving public health events. The collaboration builds upon Dyadic’s prior Andes virus monoclonal antibody work and combines the complementary expertise of Dyadic and Scripps Research to further assess the potential of Dyadic’s proprietary C1 platform for rapid development timelines, high-productivity microbial fermentation, large-scale manufacturing, and biologic production intended to support future infectious disease preparedness.

Dyadic’s microbial fungal-based C1 platform has been applied to multiple biologic modalities, including recombinant vaccine antigens and monoclonal antibodies targeting RSV, malaria, the Andes virus, Ebola, and Marburg, which is similar to Ebola and comes from the same family of viruses—the Filovirus family, and has demonstrated in preclinical studies the ability to produce monoclonal antibodies with binding, neutralization, and efficacy characteristics comparable to those generated by traditional mammalian expression systems.

$DYAI news Out - Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
https://finance.yahoo.com/sectors/healthcare/articles/dyadic-scripps-research-collaborate-rapid-112500095.html

Show me the money !!!

$DYAI Dyadic and Scripps Research team up to fast-track hantavirus antibody & vaccine development using Dyadic’s C1 platform. Read the full report: https://wix.to/pddIrSc #Biotech #Vaccine #Research #DYAI

#DYAI #NASDAQ Today’s announced collaboration with #Scripps Research is not a one-off!

It builds on years of Dyadic Applied BioSolutions’ work to address one of the world’s biggest outbreak preparedness gaps: the ability to rapidly manufacture biologics when lives are on the line.

ZAPI helped lay the foundation for pandemic preparedness applications.
CEPI (Coalition for Epidemic Preparedness Innovations)-supported work is helping advance speed.

Gates Foundation-supported programs are focused on access and affordability.

Fondazione Biotecnopolo di Siena and activities associated with the European Vaccines Hub are helping accelerate EU and global preparedness.

Now, with Scripps Research, we are applying Dyadic’s C1 platform to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, while building on prior Andes, Ebola and Marburg virus research.

C1 has demonstrated faster development timelines, high-yield microbial production, and prior human clinical safety experience, including Phase 1 evaluation of a C1-produced biologic.

That is why we believe C1 has the potential to become an enabling infrastructure platform — the #NVIDIA of #antigen and #antibody development and #biomanufacturing.

Vaccines are critical. But for those already infected, treatments — especially #monoclonal #antibodies — can be the lifeline.

The world must stop repeating the same legacy manufacturing playbook and expecting different results.

#Ebola and #hantavirus are wake-up calls.

It is time to put real muscle behind faster, higher-yield, lower-cost biologic manufacturing — to level the playing field for global health equity so no one is left behind.

See today's press release at the following link: https://dyadic.com/dyadic-and-scripps-research-collaborate-on-rapid-response-hantavirus-antibody-and-vaccine-development/

#DYAI #Biotech #BiotechStocks #PandemicPreparedness #Hantavirus #Ebola #Marburg #MonoclonalAntibodies #Vaccines #Biomanufacturing #C1Platform #ScrippsResearch #CEPI #GatesFoundation #EUVaccineHub #GlobalHealthEquity

1868 watchers on s t, 27 on here

https://investorshub.advfn.com/stock-market/NASDAQ/dyadic-DYAI/trades

News !! In .75 https://investorshub.advfn.com/stock-market/NASDAQ/dyadic-DYAI/stock-news/98624105/dyadic-and-scripps-research-collaborate-on-rapid-r

Sidoti Events, LLC's May Micro-Cap Virtual ConferenceMay 20, 2026 7:30 AM
ACCESS NewswireNEW YORK, NY / ACCESS Newswire / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Virtual Investor Conference taking place Wednesday and Thursday, May 20-21, 2026. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links. Presentation Schedule*All Times EDTWednesday, May 20, 2026 (Day 1)8:30-9:00Huize Holding Limited (HUIZ)*****9:15-9:45U Power Limited (UCAR)SuperCom (SPCB)10:00-10:30InTest Corporation (INTT)Dyadic Applied BioSolutions (DYAI)10:45-11:15International Battery Metals (IBATF)A2Z Cust2mate (AZ)11:30-12:00C1 Fund (CFND)Oil States International (OIS)12:15-12:45Heliostar Metals (HSTR)Acme United Corporation (ACU)1:00-1:30Matrix Service Company (MTRX)Horizon Aircraft (HOVR)1:45-2:15Intrusion Inc. (INTZ) 2:30-3:00ESS Tech (GWH)*****3:15-3:4520/20 Biolabs, Inc. (AIDX)*****4:00-4:30***** 1x1s Only(20th)Bassett Furniture (BSET)****************All Times EDTThursday, May 21, 2026 (Day 2)8:30-9:00Owlting Group (OWLS)Einride (LEGT)9:15-9:45Mastech Digital, Inc. (MHH)CBAK Energy Technology (CBAT)10:00-10:30Cabbacis (CABI)Electra AI (IRHO)10:45-11:15Intellicheck (IDN)*****11:30-12:00Harvard Bioscience, Inc. (HBIO)Stakeholder Gold Corporation (SRC)12:15-12:45*****First Phosphate (FRSPF)1:00-1:30SafeSpace Global Corp. (SSGC)*****1:45-2:15Myomo, Inc (MYO)*****2:30-3:00Flexsteel Industries, Inc. (FLXS)*****3:15-3:45Oragenics, Inc. (OGEN)Power Metallic Mines (PNPNF)4:00-4:30Highland Copper Company (HDRSF)*****1x1s Only(21st)Bassett Furniture (BSET)***************About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")
In 2023, Sidoti & Company, LLC formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the over 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti's coverage universe comprises approximately 130 equities, of which over 80 percent participate in the firm's rapidly growing Company Sponsored Research ("CSR") program. Events is a leading provider of corporate access through the many investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Events benefits from Sidoti's small- and microcap-focused nationwide sales force, which has connections with over 2,500 institutional relationships in North America. This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.Media Contact:Ally Cecil
Conference Coordiantor

$DYAI - Dyadic International, Inc. Q1 2026 Earnings Call Summary
https://finance.yahoo.com/sectors/healthcare/articles/dyadic-international-inc-q1-2026-123000033.html

$DYAI Dyadic Applied BioSolutions will present at the Sidoti Virtual Investor Conference May 20–21. Joe Hazelton, President & COO, will share company updates on our animal-free protein & enzyme platforms.

Details: https://www.stockonhighalert.com/post/dyai-dyadic-applied-biosolutions-announces-participation-in-sidoti-virtual-investor-conference

#Dyadic #Biotech #InvestorNews @TheBullRunShow

$DYAI ~ Dyadic International Inc (DYAI) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...


https://finance.yahoo.com/sectors/healthcare/articles/dyadic-international-inc-dyai-q1-050138744.html

$DYAI ~ announced that it will report its financial results for the quarter ended March 31, 2026 and host a corporate update conference call on Wednesday, May 13, 2026. https://finance.yahoo.com/sectors/healthcare/articles/dyadic-report-q1-2026-financial-200500766.html

Dyadic International Inc ($DYAI) Q1 2026: Everything You Need To Know Ahead Of Earnings
https://finance.yahoo.com/markets/stocks/articles/dyadic-international-inc-dyai-q1-132313204.html

$DYAI Latest SEC Filings
[SCHEDULE 13G] DYADIC INTERNATIONAL INC Passive Investment Disclosure (>5%) May 11, 2026

$DYAI News : Francisco Trust discloses 4.36M-share stake in Dyadic (NASDAQ: DYAI), note amended

Dyadic International Inc. reports beneficial ownership by Francisco Trust via Thomas Emalfarb, Trustee. The filing states Francisco Trust beneficially owns 4,363,045 shares (11.97%) of common stock. The trust also holds 952,381 shares issuable upon conversion of a Convertible Note amended to a $1.05 conversion price on 12/23/2025, with maturity extended to 12/31/2027. Shares outstanding were 36,438,703 as of 03/24/2026.


https://www.stocktitan.net/sec-filings/DYAI/schedule-13g-a-dyadic-international-inc-amended-passive-investment-di-cf2067d5163f.html

$DYAI - Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information, please visit www.dyadic.com.

$DYAI Chart looking good here! Must check

Dyadic International, Inc. (DYAI) $DYAI News!

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
https://finance.yahoo.com/sectors/healthcare/articles/dyadic-report-q1-2026-financial-200500766.html

🚨 $DYAI ON HIGH ALERT 🚨

Dyadic is shifting from R&D platform story to commercial biotech execution. https://www.stockonhighalert.com/post/stock-alert-dyai-dyadic-applied-biosolutions-builds-commercial-catalyst-stack-across-recombin

✅ AlbuFree™ DX commercial launch
✅ DNase I launched with Fermbox Bio
✅ IBT Bioservices OEM distribution deal
✅ Recombinant DNase I + transferrin products
✅ BRIG Bio nutrition agreement
✅ C1 + Dapibus™ protein production platforms

Animal-free recombinant protein catalyst stack heating up.

$DYAI #Biotech #SmallCaps

A recent article confidently showcases Dyadic Applied BioSolutions (Nasdaq: #DYAI) and its innovative fungal-based protein production platforms. This game-changing technology is set to revolutionize the manufacturing of enzymes and proteins, making it scalable, efficient, and cost-effective.

Read more: https://www.ad-hoc-news.de/boerse/news/ueberblick/dyadic-international-stock-pioneering-fungal-protein-platforms-for/69060732

#TheBullRunShow #biotech #biomanufacturing #enzymes #proteins #manufacturing #innovation #investing #stocks #nasdaq #news #Sustainability

🚀 $DYAI is transitioning from R&D to a commercial powerhouse!

Key 2025/2026 Milestones:
✅ Commercial launch of AlbuFree™ DX with Proliant
✅ Expanded partnership with Fermbox Bio & product launch
✅ New distribution deal with IBT Bioservices 🌍
✅ $8.6M cash to fuel the pipeline

Read the full update: https://dyadic.com/dyadic-announces-2025-financial-results-and-highlights-recent-company-progress/

$DYAI Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
https://finance.yahoo.com/news/dyadic-applied-biosolutions-announces-commercial-112000161.html

🚨 $DYAI ALERT – FIRST COMMERCIAL PRODUCT LAUNCHED TODAY! 🔥🧬💥

👉👉https://finance.yahoo.com/news/dyadic-fermbox-bio-launch-first-122000658.html

🔹Dyadic + Fermbox Bio just dropped animal-origin-free Recombinant DNase I (RNase-Free) – FIRST product under expanded collab! Animal-free biotech beast transitioning HARD to sales + recurring rev in life sciences!

🔹Fresh off Inzymes dairy enzyme milestone ($200K cash + royalties in $1.5–$2B market) – 2026 commercialization ramp loading. Sustainable proteins play exploding!

🔹Nasdaq micro-cap with catalyst volume spikes – traders: pops incoming. Investors: diamond hands on green biotech revolution.

🔹Don't fade this undervalued runner! 📈🌱
🚨 $DYAI ALERT – FIRST COMMERCIAL PRODUCT LAUNCHED TODAY! 🔥🧬💥

👉👉https://t.co/FgNcTWr6wc

🔹Dyadic + Fermbox Bio just dropped animal-origin-free Recombinant DNase I (RNase-Free) – FIRST product under expanded collab! Animal-free biotech beast transitioning HARD to sales +… pic.twitter.com/6qnIUfH3U2— 🚨StockOnHighAlert🚀 (@Stock_HighAlert) March 4, 2026

$DYAI Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
https://finance.yahoo.com/news/dyadic-applied-biosolutions-inzymes-aps-122000468.html

$DYAI - The launch of AlbuFree™ DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales of recombinant human albumin products.

“This launch is a clear validation of Dyadic’s technology and our commercialization strategy,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. “Recombinant human albumin is a well-understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner-driven commercialization model.”

Recombinant human albumin is a critical component in cell culture media and other life science applications, where demand is rising for animal-free, scalable, and supply-secure inputs. The launch of AlbuFree™ DX marks the first major commercial step in Dyadic’s growing portfolio of market-specific proteins and represents an important milestone in converting licensed programs into recurring revenue streams.

https://finance.yahoo.com/news/dyadic-applied-biosolutions-proliant-health-122500745.html

$DYAI News! Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
https://finance.yahoo.com/news/dyadic-applied-biosolutions-proliant-health-122500745.html

$DYAI The Engine of Innovation: Dyadic and Proliant’s Commercial Breakthrough.Perfect Match.

yadda, yadda, yadda

$DYAI " The launch of AlbuFree™ DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the terms of the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales of recombinant human albumin products.

“This launch is a clear validation of Dyadic’s technology and our commercialization strategy,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. “Recombinant human albumin is a well-understood product with broad adoption in cell culture and life science applications, making it an ideal fit for our platform and partner-driven commercialization model.”

Recombinant human albumin is a critical component in cell culture media and other life science applications, where demand is rising for animal-free, scalable, and supply-secure inputs. The launch of AlbuFree™ DX marks the first major commercial step in Dyadic’s growing portfolio of market-specific proteins and represents an important milestone in converting licensed programs into recurring revenue streams.

$DYAI News Out! Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin https://finance.yahoo.com/news/dyadic-applied-biosolutions-proliant-health-122500745.html

dyai...................................P/M

DYAI.................................................................https://stockcharts.com/h-sc/ui?s=dyai&p=W&b=5&g=0&id=p86431144783

$DYAI EMA Analysis: https://stockta.com/cgi-bin/analysis.pl?symb=DYAI&mode=table&table=ema

$DYAI - “We see this as a pivotal moment for Dyadic,” said Joe Hazelton, Dyadic’s President and COO. “We’ve proven the commercial readiness of our platforms with valuable partnerships and revenue. Now we’re aligning our organization to scale and expand across the life sciences, food, and nutrition markets. I look forward to working with our leadership team to work to accelerate this momentum, drive operational execution, and deliver tangible value to our shareholders.”

Dyadic’s C1 and Dapibus™ platforms—already central to its recent commercial successes—continue to underpin the Company’s strategy, offering differentiated, large-scale, high-titer production of recombinant proteins across targeted non-therapeutic markets.

While the significant majority of Dyadic’s focus will be on the compelling ancillary protein opportunity, legacy biopharmaceutical programs remain active, with Mr. Emalfarb (who will continue to serve as Chief Executive Officer and a member of the Board of Directors) overseeing their development in addition to his continued focus on funding/investment opportunities, IP strategy, and legacy projects.

READ MORE FULL INFO HERE - https://finance.yahoo.com/news/dyadic-announces-leadership-change-part-123500143.html

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
https://www.barchart.com/story/news/32167547/dyadic-to-report-first-quarter-2025-financial-results-on-wednesday-may-14-2025

more like rearranging the deck chairs (on the Titanic?)

$DYAI News Out! Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets

Leadership team realigned in order to enable execution of ancillary protein strategy

Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad

JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets. Dyadic’s Board of Directors, which has overseen and endorsed this strategy, has appointed Joe Hazelton as President, effective immediately. Mr. Hazelton will also continue in his role as Chief Operating Officer.

Over the past 18 months, Dyadic has made a deliberate pivot to prioritize near-term commercialization opportunities in high-growth, high-value segments such as cell culture media, DNA/RNA technologies, and non-animal food and nutrition ingredients. This pivot has achieved commercial validation through the consummation of high value transactions in the ancillary protein space, including a develop-and-commercialize partnership with Proliant Health and Biologicals for recombinant human albumin, a collaboration with a non-animal dairy enzyme company, and a joint venture with Fermbox Bio that led to the launch of EN3ZYME, recently resulting in a significant purchase order in the cellulosic enzyme market.

“We believe the achievement of these milestones validates our strategy and reflects the growing demand for ancillary recombinant proteins,” said Mark Emalfarb, Dyadic’s Founder and Chief Executive Officer. “We previously communicated an initial focus in the ancillary protein space, we have successfully executed on key initial agreements, and now we are reaffirming that focus by aligning our leadership team to accelerate growth. Joe’s appointment as President ensures focused and prioritized execution across Dyadic’s technical, operational and commercial efforts.”

As President, Joe Hazelton will be responsible for scaling Dyadic’s scientific and commercial initiatives, deepening industry partnerships, oversight of daily operations and ensuring efficient execution of the business strategy. In support of this strategic shift, Joe will also guide Dyadic’s corporate rebranding efforts.

“We see this as a pivotal moment for Dyadic,” said Joe Hazelton, Dyadic’s President and COO. “We’ve proven the commercial readiness of our platforms with valuable partnerships and revenue. Now we’re aligning our organization to scale and expand across the life sciences, food, and nutrition markets. I look forward to working with our leadership team to work to accelerate this momentum, drive operational execution, and deliver tangible value to our shareholders.”

https://finance.yahoo.com/news/dyadic-announces-leadership-change-part-123500143.html

$DYAI News : Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Expanded life science and industrial portfolio with six additional life science products in development

Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme markets

Up to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)

Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programs

Selected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.

Scientific Pre-Publication - "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1”

Cash, cash equivalents and investment-grade securities of $7.4 million as of March 31, 2025

Financial results and business update conference call scheduled for 5:00 pm ET today

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a biotechnology company specializing in the development of functional recombinant solutions and proprietary production strains to manufacture large quantities of precision-engineered proteins and enzymes for use in life science, nutrition, and industrial applications, today announced its financial results for the first quarter 2025, highlighting significant progress toward commercializing its proprietary Dapibus™ and C1 microbial protein production platforms and driving long-term growth opportunities.

"While we continue to support select biopharmaceutical initiatives through fully funded partnerships with organizations such as CEPI, the Gates Foundation, and Fondazione Biotecnopolo di Siena ("FBS”), our primary focus is on developing and commercializing scalable products with recurring revenue potential. This strategic pivot is aimed at driving sustainable growth in sectors with strong demand and clear market opportunities,” said Mark Emalfarb, CEO of Dyadic. "We believe we are making meaningful progress in returning to Dyadic's core strength, utilizing our proprietary microbial protein production platforms, like C1 and Dapibus, to drive revenue growth in high-value life sciences, bioactives, ingredients, and industrial markets such as cell culture media, nucleic and other enzymes.”

Mr. Emalfarb continued, "Looking ahead, Dyadic remains committed to expanding the reach of our C1 and Dapibus™ platforms by developing functional recombinant solutions for non-therapeutic applications that can be both commercialized and licensed. With a growing network of partners and increased support from non-dilutive funding sources, we believe Dyadic is well-positioned to advance innovation, broaden global access to affordable biologics, proteins and enzymes, and lower production costs, ultimately providing a stable foundation for long-term shareholder value.” https://finance.yahoo.com/news/dyadic-reports-first-quarter-2025-200500991.html

$DYAI Watch - Dyadic International, #NASDAQ Exciting Update! Wow! via
@YouTube

$DYAI Looking Toward Product Revenues

Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin and bovine alpha-lactalbumin. Dyadic’s partner is expected to first focus on research grade product, but will be able to expand into the excipient grade and current good manufacturing practices (cGMP) grade product as the market matures.

https://finance.yahoo.com/news/dyai-looking-toward-product-revenues-092700269.html

.$DYAI Dyadic’s partner is expected to first focus on research grade product, but will be able to expand into the excipient grade and current good manufacturing practices (cGMP) grade product as the market matures.

https://finance.yahoo.com/news/dyai-looking-toward-product-revenues-092700269.html

$DYAI Dyadic International: Proteins for World Health DYAI NASDAQ detailed its product portfolio, vaccines

$DYAI Buy Opinion from barchart https://www.barchart.com/stocks/quotes/DYAI/opinion

$ADMQ CEO INTERVIEW -

$DYAI Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical and bio-industrial products for human and animal health and alternative proteins.

https://dyadic.com/

$DYAI Barchart Buy Opinion - https://www.barchart.com/stocks/quotes/DYAI/opinion

DYAI, under $2